Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison M Layton

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
BMJ (Clinical Research Ed.)|May 16, 2023
Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trialMiriam Santer, Megan Lawrence, Susanne Renz, et al.
JAAD International|June 5, 2023
The Personalized Acne Treatment Tool - Recommendations to facilitate a patient-centered approach to acne management from the Personalizing Acne: Consensus of ExpertsAlison M Layton, Andrew Alexis, Hilary Baldwin, et al.
Plos Neglected Tropical Diseases|August 29, 2024
Development of a Core Outcome Measure Instrument; "LeishCOM_LCL", for Localised Cutaneous LeishmaniasisShalindra Ranasinghe, Sujai Senarathne, Vijani Somaratne, et al.
Nature Communications|January 12, 2021
Characterization of a new Leishmania major strain for use in a controlled human infection modelHelen Ashwin, Jovana Sadlova, Barbora Vojtkova, et al.
BMJ Open|December 11, 2023
Cost-effectiveness of Spironolactone for Adult Female Acne (SAFA): economic evaluation alongside a randomised controlled trialSarah Pyne, Tracey H Sach, Megan Lawrence, et al.
Trials|August 27, 2025
Social media recruitment enhances participant diversity in dermatology clinical trial: findings from the SAFA trialCherish Boxall, Susanne Renz, Beth Stuart, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 30, 2021
Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in SudanBrima M Younis, Mohamed Osman, Eltahir A G Khalil, et al.
Journal of the American Academy of Dermatology|March 18, 2019
Navigating the landscape of core outcome set development in dermatologyCecilia A C Prinsen, Phyllis I Spuls, Jan Kottner, et al.
Molecular Therapy. Methods & Clinical Development|September 10, 2024
A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasisBrima M Younis, Rebecca Wiggins, Eltahir A G Khalil, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 18, 2026
Update of the EuroGuiDerm evidence-based guideline for the treatment of acne-Short versionAlexander Nast, Bassel H Al Wattar, Marie Beylot Barry, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
BMJ (Clinical Research Ed.)|May 16, 2023
Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trialMiriam Santer, Megan Lawrence, Susanne Renz, et al.
JAAD International|June 5, 2023
The Personalized Acne Treatment Tool - Recommendations to facilitate a patient-centered approach to acne management from the Personalizing Acne: Consensus of ExpertsAlison M Layton, Andrew Alexis, Hilary Baldwin, et al.
Plos Neglected Tropical Diseases|August 29, 2024
Development of a Core Outcome Measure Instrument; "LeishCOM_LCL", for Localised Cutaneous LeishmaniasisShalindra Ranasinghe, Sujai Senarathne, Vijani Somaratne, et al.
Nature Communications|January 12, 2021
Characterization of a new Leishmania major strain for use in a controlled human infection modelHelen Ashwin, Jovana Sadlova, Barbora Vojtkova, et al.
BMJ Open|December 11, 2023
Cost-effectiveness of Spironolactone for Adult Female Acne (SAFA): economic evaluation alongside a randomised controlled trialSarah Pyne, Tracey H Sach, Megan Lawrence, et al.
Trials|August 27, 2025
Social media recruitment enhances participant diversity in dermatology clinical trial: findings from the SAFA trialCherish Boxall, Susanne Renz, Beth Stuart, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 30, 2021
Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in SudanBrima M Younis, Mohamed Osman, Eltahir A G Khalil, et al.
Journal of the American Academy of Dermatology|March 18, 2019
Navigating the landscape of core outcome set development in dermatologyCecilia A C Prinsen, Phyllis I Spuls, Jan Kottner, et al.
Molecular Therapy. Methods & Clinical Development|September 10, 2024
A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasisBrima M Younis, Rebecca Wiggins, Eltahir A G Khalil, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 18, 2026
Update of the EuroGuiDerm evidence-based guideline for the treatment of acne-Short versionAlexander Nast, Bassel H Al Wattar, Marie Beylot Barry, et al.
Pageof 7